Kaplan–Meier survival analysis showed that NSCLC patients with FAT1 mutations had a significantly better survival outcome than wild-type patients (median survival time: 23.0 vs. 6.5 months, Log-rank test P = 0.048; Fig. 4a). This evidence concerns the gene FAT1 and non-small cell lung carcinoma.